Clinical Trial Update: An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients [Phase 2]

View source ↗

Summary

This Phase 2 open-label pharmacokinetic/pharmacodynamic trial evaluated CPX-351 (cytarabine:daunorubicin liposome injection) for potential QTc prolongation in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Status: COMPLETED | Results posted: 2017-11-30